<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794505</url>
  </required_header>
  <id_info>
    <org_study_id>F-2018-3401-056</org_study_id>
    <nct_id>NCT03794505</nct_id>
  </id_info>
  <brief_title>Quality of Life and Pain With Infiltration or Suprascapular Nerve Block in Glenohumeral Arthirtis</brief_title>
  <official_title>Health Related Quality of Life and Pain Managment Using Infiltration or Suprascapular Nerve Block Ultrasound Guided in Patients With Glenohumeral Arthirtis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy in pain and health related quality of life of suprascapular nerve block ultrasound
      guided and glenohumeral infiltration in glenohumeral arthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the efficacy in pain management and health related quality of life of
      suprascapular nerve block ultrasound guided and glenohumeral infiltration in patients with
      glenohumeral arthritis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain before</measure>
    <time_frame>VAS before intervention</time_frame>
    <description>visual analogue scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain 2 months after</measure>
    <time_frame>VAS 2 months after</time_frame>
    <description>Visual analogue scale 2 months after procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain 6 months after</measure>
    <time_frame>VAS 6 months after</time_frame>
    <description>Visual analogue scale 6 months after procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life before procedure</measure>
    <time_frame>SF12v2 before procedure</time_frame>
    <description>SF12v2 Health related quality of life before procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 2 months after procedure</measure>
    <time_frame>SF12v2 2 months after</time_frame>
    <description>SF12v2 Health related quality of life 2 months after</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 6 months after procedure</measure>
    <time_frame>SF12v2 6 months after</time_frame>
    <description>SF12v2 Health related quality of life 6 months after</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Shoulder Arthritis</condition>
  <arm_group>
    <arm_group_label>Shoulder infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suprascapular nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone Acetate</intervention_name>
    <description>depo-medrol 40 mg</description>
    <arm_group_label>Shoulder infiltration</arm_group_label>
    <arm_group_label>Suprascapular nerve block</arm_group_label>
    <other_name>depo-medrol 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 2% Injectable Solution</intervention_name>
    <description>2ml of 2% lidocaine</description>
    <arm_group_label>Shoulder infiltration</arm_group_label>
    <other_name>xilocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine HCl Inj 7.5 MG/ML</intervention_name>
    <description>25 mg</description>
    <arm_group_label>Suprascapular nerve block</arm_group_label>
    <other_name>Ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IMSS affiliated

          -  Glenohumeral arthritis diagnosed

        Exclusion Criteria:

          -  Previusly treatment for the same disease

          -  No follow up

          -  Dead
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Alonso Calderon Cordova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Orthopedics, UMAE &quot;Dr. Victorio de la Fuente Narváez&quot; IMSS-UNAM. Ciudad de México, México</name>
      <address>
        <city>Mexico City</city>
        <state>Gustavo A Madero</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>January 5, 2019</last_update_submitted>
  <last_update_submitted_qc>January 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Luis Alonso Calderon Cordova</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

